NASDAQ:TSHA

Taysha Gene Therapies News Headlines

$23.86
-1.05 (-4.22 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$23.39
Now: $23.86▼
$25.32
50-Day Range
$19.29
MA: $23.81▼
$29.36
52-Week Range
$18.16
Now: $23.86▼
$33.35
Volume89,203 shs
Average Volume91,715 shs
Market Capitalization$900.98 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Taysha Gene Therapies (NASDAQ TSHA) News Headlines Today

SourceHeadline
Taysha Gene Therapies (NASDAQ:TSHA) Sees Large Volume IncreaseTaysha Gene Therapies (NASDAQ:TSHA) Sees Large Volume Increase
americanbankingnews.com - April 15 at 11:40 AM
Oppenheimer Analysts Cut Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Oppenheimer Analysts Cut Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)
americanbankingnews.com - April 15 at 7:46 AM
William Blair Weighs in on Taysha Gene Therapies, Inc.s Q1 2021 Earnings (NASDAQ:TSHA)William Blair Weighs in on Taysha Gene Therapies, Inc.'s Q1 2021 Earnings (NASDAQ:TSHA)
americanbankingnews.com - April 15 at 6:18 AM
BRIEF-Taysha Gene Therapies Announces New Data On Multiple Preclinical Programs And Upcoming Research And Development DayBRIEF-Taysha Gene Therapies Announces New Data On Multiple Preclinical Programs And Upcoming Research And Development Day
msn.com - April 14 at 10:48 AM
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 4.8% After Analyst UpgradeTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 4.8% After Analyst Upgrade
americanbankingnews.com - April 13 at 11:58 AM
Taysha Gene Therapies (NASDAQ:TSHA) PT Raised to $43.00 at Morgan StanleyTaysha Gene Therapies (NASDAQ:TSHA) PT Raised to $43.00 at Morgan Stanley
americanbankingnews.com - April 13 at 11:20 AM
Taysha Gene Therapies Stock Is Trading Higher After Buying Rights To New Gene Therapy Candidate For Neurodegenerative DiseaseTaysha Gene Therapies Stock Is Trading Higher After Buying Rights To New Gene Therapy Candidate For Neurodegenerative Disease
finance.yahoo.com - April 12 at 6:38 PM
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $67.50 at Chardan CapitalTaysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $67.50 at Chardan Capital
americanbankingnews.com - April 12 at 5:00 PM
Why Taysha Gene Therapiess Stock is Trading Higher TodayWhy Taysha Gene Therapies's Stock is Trading Higher Today
msn.com - April 12 at 1:37 PM
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $21.19Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $21.19
americanbankingnews.com - April 12 at 11:12 AM
BRIEF-Taysha Gene Therapies Acquires Exclusive Worldwide Rights To Clinical-Stage Aav9 Gene Therapy Program, Now Known As Tsha-120, For Giant Axonal NeuropathyBRIEF-Taysha Gene Therapies Acquires Exclusive Worldwide Rights To Clinical-Stage Aav9 Gene Therapy Program, Now Known As Tsha-120, For Giant Axonal Neuropathy
msn.com - April 12 at 8:36 AM
Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative DiseaseTaysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative Disease
finance.yahoo.com - April 12 at 8:36 AM
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare ConferencesTaysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
finance.yahoo.com - April 5 at 7:42 AM
Financial Review: Surface Oncology (NASDAQ:SURF) versus Taysha Gene Therapies (NASDAQ:TSHA)Financial Review: Surface Oncology (NASDAQ:SURF) versus Taysha Gene Therapies (NASDAQ:TSHA)
americanbankingnews.com - March 30 at 6:36 PM
Brokerages Expect Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Will Post Earnings of -$0.45 Per Share Brokerages Expect Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Will Post Earnings of -$0.45 Per Share
americanbankingnews.com - March 30 at 4:56 AM
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $21.54Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $21.54
americanbankingnews.com - March 29 at 1:46 PM
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by BrokeragesTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Brokerages
americanbankingnews.com - March 29 at 9:02 AM
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $22.47Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $22.47
americanbankingnews.com - March 25 at 10:54 AM
Heres Why Were Not Too Worried About Taysha Gene Therapies (NASDAQ:TSHA) Cash Burn SituationHere's Why We're Not Too Worried About Taysha Gene Therapies' (NASDAQ:TSHA) Cash Burn Situation
finance.yahoo.com - March 24 at 3:08 PM
Taysha Gene Therapies (NASDAQ:TSHA) Sees Unusually-High Trading VolumeTaysha Gene Therapies (NASDAQ:TSHA) Sees Unusually-High Trading Volume
americanbankingnews.com - March 24 at 11:54 AM
Taysha Gene Therapies Announces Collaboration to Advance Next-Generation Mini-Gene Payloads for an AAV Gene Therapy for the Treatment of Neurodevelopmental DisordersTaysha Gene Therapies Announces Collaboration to Advance Next-Generation Mini-Gene Payloads for an AAV Gene Therapy for the Treatment of Neurodevelopmental Disorders
finance.yahoo.com - March 9 at 10:07 AM
Taysha Gene Therapies Inc to Host Earnings CallTaysha Gene Therapies Inc to Host Earnings Call
finance.yahoo.com - March 3 at 7:32 AM
Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate UpdateTaysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update
finance.yahoo.com - March 3 at 7:32 AM
Taysha Gene Therapies to Release Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 3Taysha Gene Therapies to Release Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 3
finance.yahoo.com - March 1 at 8:29 AM
Taysha Gene Therapies Announces Support of Rare Disease Day 2021Taysha Gene Therapies Announces Support of Rare Disease Day 2021
finance.yahoo.com - February 26 at 10:10 AM
Taysha Gene Therapies Announces Formation of Independent Scientific Advisory BoardTaysha Gene Therapies Announces Formation of Independent Scientific Advisory Board
finance.yahoo.com - February 16 at 8:29 AM
Taysha Gene Therapies Announces Participation in Upcoming Investor Healthcare ConferencesTaysha Gene Therapies Announces Participation in Upcoming Investor Healthcare Conferences
finance.yahoo.com - February 10 at 8:32 AM
Taysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic Epilepsies and Additional CNS ...Taysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic Epilepsies and Additional CNS ...
businesswire.com - February 9 at 10:28 PM
Taysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic Epilepsies and Additional CNS DisordersTaysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic Epilepsies and Additional CNS Disorders
finance.yahoo.com - February 9 at 7:26 AM
Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People OfficerTaysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People Officer
finance.yahoo.com - January 26 at 9:01 AM
Taysha Gene Therapies, Inc.Taysha Gene Therapies, Inc.
realmoney.thestreet.com - January 21 at 6:53 PM
Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 DeficiencyTaysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency
finance.yahoo.com - January 19 at 5:28 PM
Taysha Gene Therapies and UT Southwestern Medical Center Launch Innovation Fund to Accelerate Advancement of AAV Gene Therapies for Monogenic Diseases of the Central Nervous SystemTaysha Gene Therapies and UT Southwestern Medical Center Launch Innovation Fund to Accelerate Advancement of AAV Gene Therapies for Monogenic Diseases of the Central Nervous System
finance.yahoo.com - January 13 at 10:45 AM
Taysha Gene Therapies Announces Collaboration with AllStripes on SURF1-Associated Leigh Syndrome Clinical Development and Natural HistoryTaysha Gene Therapies Announces Collaboration with AllStripes on SURF1-Associated Leigh Syndrome Clinical Development and Natural History
finance.yahoo.com - January 4 at 8:28 AM
Taysha Gene Therapies Expands Leadership Team to Deepen Manufacturing and Communications CapabilitiesTaysha Gene Therapies Expands Leadership Team to Deepen Manufacturing and Communications Capabilities
finance.yahoo.com - December 29 at 7:54 AM
What You Need To Know About Taysha Gene Therapies, Inc.s (NASDAQ:TSHA) Investor CompositionWhat You Need To Know About Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Investor Composition
finance.yahoo.com - December 24 at 12:59 PM
Taysha Gene Therapies Announces Queen’s University’s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 GangliosidosisTaysha Gene Therapies Announces Queen’s University’s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
finance.yahoo.com - December 21 at 9:29 AM
Taysha Gene Therapies Announces New cGMP Gene Therapy Manufacturing FacilityTaysha Gene Therapies Announces New cGMP Gene Therapy Manufacturing Facility
finance.yahoo.com - December 17 at 5:41 PM
Is TSHA A Good Stock To Buy Now?Is TSHA A Good Stock To Buy Now?
finance.yahoo.com - December 17 at 12:52 AM
Taysha Gene Therapies Set to Join Russell 2000® Index on December 21, 2020Taysha Gene Therapies Set to Join Russell 2000® Index on December 21, 2020
finance.yahoo.com - December 15 at 9:01 AM
Taysha Gene Therapies Inc.Taysha Gene Therapies Inc.
marketwatch.com - December 7 at 1:50 AM
Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-103 for the Treatment of Epilepsy Caused by SLC6A1 HaploinsufficiencyTaysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-103 for the Treatment of Epilepsy Caused by SLC6A1 Haploinsufficiency
finance.yahoo.com - December 3 at 10:54 AM
Taysha Gene Therapies Adds Industry-Leading Gene Therapy Executives to Board of DirectorsTaysha Gene Therapies Adds Industry-Leading Gene Therapy Executives to Board of Directors
finance.yahoo.com - November 24 at 7:31 AM
Taysha Gene Therapies Reports Third Quarter 2020 Financial Results and Provides Business UpdateTaysha Gene Therapies Reports Third Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 12 at 5:32 PM
Tayshas gene therapy nabs Orphan Drug and Rare Pediatric status for inherited neurological disorderTaysha's gene therapy nabs Orphan Drug and Rare Pediatric status for inherited neurological disorder
seekingalpha.com - October 27 at 1:54 PM
Taysha nabs Orphan Drug and Rare Pediatric status for Rett syndrome gene therapyTaysha nabs Orphan Drug and Rare Pediatric status for Rett syndrome gene therapy
seekingalpha.com - October 14 at 4:48 PM
This page was last updated on 4/16/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.